The prognostic value of pretreatment platelet count in patients with head and neck squamous cell carcinoma

Publication date: June 2017
Source:Auris Nasus Larynx, Volume 44, Issue 3
Author(s): Laura Pardo, Cristina Valero, Montserrat López, Jacinto García, Mercedes Camacho, Miquel Quer, Xavier León
ObjectiveThrombocytosis is commonly observed in patients with solid tumors. This study aimed to evaluate the prognostic role of circulating pretreatment platelet count in a large series of patients with head and neck squamous cell carcinoma (HNSCC).MethodsWe retrospectively studied 824 patients with HNSCC treated at a single institution from 2000 to 2012. Disease-specific survival and local, regional, and distant recurrence-free survival were analyzed according to the distribution of the platelet count.ResultsBy defining the platelet count 250.05×10⁹/L as a cut-off point with the best predictive capacity, we classified the patients into two groups: those with a high platelet count (n=378, 45.9%), and those with a low platelet count (n=446, 54.1%). On univariate analysis, there were significant differences in disease-specific survival depending on pretreatment platelet count (P=0.001). The 5-year specific survival rates were 74.1% (CI 95%: 69.8–78.4%) and 61.6% (CI 95%: 56.4–66.8%) for patients with a low and high platelet count, respectively. According to the results of a multivariate analysis, patients with a high count of platelets had a tendency to a lower disease-specific survival, but the hazard ratio did not reach statistically significant differences (HR 1.24, CI 95%: 0.97–1.61, P=0.085).ConclusionPlatelet count was significantly associated with survival in univariate analysis. However, in a multivariate analysis it lost its prognostic capacity, limiting its utility as a prognostic marker in patients with HNSCC. Considering separately each primary tumor location, patients with hypopharyngeal cancer and a high platelet count had a significant decrease of disease-specific survival.



http://ift.tt/2mfPvNb